---
schema_version: "secwatch.filing_event.v1"
accession: "0001663577-24-000143"
form_type: "8-K"
ticker: "SKVI"
cik: "0001085277"
company_name: "SKINVISIBLE, INC."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:35:38.512725+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare

## Summary
- Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.
- Uses proprietary Invisicare technology; studies show up to 10x increase in transdermal delivery effectiveness.
- Aims to offer needle-free alternative to injections for obesity drugs; potential to improve compliance.
- Global obesity drug market projected to exceed $30B by 2027.
- Company actively seeking strategic partnerships for development.

## SEC filing metadata
- accession: 0001663577-24-000143
- form_type: 8-K
- ticker: SKVI
- cik: 0001085277
- company_name: SKINVISIBLE, INC.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/0001663577-24-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/skvi8k052924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001663577-24-000143
- JSON: https://secwatch.observer/filing/0001663577-24-000143.json
- Plain text: https://secwatch.observer/filing/0001663577-24-000143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.